Abstract Body

Interferon gamma release assays (IGRA) and tuberculin skin tests (TST) have poor sensitivity for latent TB infection (LTBI) among people living with HIV/AIDS (PLHIV). By combining CD4 and CD8 mediated immune responses, the new IGRA, QuantiFERON®-TB Gold Plus (QFT®-Plus; QIAGEN), may perform better among PLHIV. We investigated QFT®-Plus sensitivity for active TB (used as a surrogate for LTBI) in a Zambian TB clinic.

Consecutive smear or Xpert MTB/RIF positive adult (≥18years) pulmonary TB patients were recruited between 06/2015-03/2016. Venous blood was tested with QFT®-Plus. All participants were tested for HIV. Using logistic regression, factors associated with positive QFT®-Plus results were explored. Due to the small number of negative/indeterminate results, individual factors were adjusted for age alone.

Among N=108 patients (median age 32 [interquartile range 27-38] years; 73% male and 63% HIV-positive), there were 90 QFT®-Plus positive, 11 negative and seven indeterminate results; sensitivity 83% (95% confidence interval [CI] 75-90%). There was no difference in sensitivity by HIV-status (HIV-positive 85% [95%CI 75-93%; n=68] and HIV-negative 80% [95%CI 64-91%; n=40]; p=0.59). Among PLHIV, sensitivity was lower when CD4 counts were <100cells/µl (50% [95%CI 16-84%]; n=8) compared with ≥100cells/µl (89% [95%CI 75-96%]; n=44) (p=0.02). In models adjusted for age, CD4 count <100cells/µl (odds ratio [OR] 0.15 [95%CI 0.02-0.96]; p=0.05), and, body mass index <18.5Kg/m2 (OR 0.27 [95%CI 0.08-0.91]; p=0.02), were associated with decreased odds of positive QFT®-Plus results. A study conducted at the same clinic in 2007 using the same methods estimated QuantiFERON®-TB Gold In-Tube (QGIT; QIAGEN) and TST sensitivity in a similar population, allowing QFT®-Plus, QGIT and TST sensitivity to be summarised. The overall QFT®-Plus sensitivity was similar to QGIT and TST, with comparable sensitivities among HIV-uninfected patients (Table). However, QFT®-Plus sensitivity was higher among PLHIV, when compared with QGIT and TST. While point estimates suggest QFT®-Plus sensitivity maybe higher than QGIT sensitivity in PLHIV with CD4 counts <100cell/µl, the small numbers in the stratum with wide CIs preclude any firm conclusions.

Overall QFT®-Plus sensitivity is similar to QGIT and TST, but in contrast to these, sensitivity is not affected by HIV-status. QFT®-Plus improves LTBI diagnosis among PLHIV with implications for the management of LTBI in this population.